SUMMARY Diffuse large B cell lymphoma (DLBCL) is the most common form of blood cancer and is characterized by a striking degree of genetic and clinical heterogeneity. This heterogeneity poses a major barrier to understanding the genetic basis of the disease and its response to therapy. Here, we performed an integrative analysis of whole exome sequencing and transcriptome sequencing in a cohort of 1001 DLBCL patients to comprehensively define the landscape of 150 genetic drivers of the disease. We characterized the functional impact of these genes using an unbiased CRISPR screen of DLBCL cell lines to define oncogenes that promote cell growth. A prognostic model comprising these genetic alterations outperformed current established methods: cell of origin, the International Prognostic Index comprising clinical variables, and dual MYC and BCL2 expression. These results comprehensively define the genetic drivers and their functional roles in DLBCL to identify new therapeutic opportunities in the disease.

No abstract

Hepatosplenic T cell lymphoma (HSTL) is a rare and lethal lymphoma; the genetic drivers of this disease are unknown. Through whole exome sequencing of 68 HSTLs, we define recurrently mutated driver genes and copy number alterations in the disease. Chromatin modifying genes including SETD2, INO80 and ARID1B were commonly mutated in HSTL, affecting 62% of cases. HSTLs manifest frequent mutations in STAT5B (31%), STAT3 (9%), and PIK3CD (9%) for which there currently exist potential targeted therapies. In addition, we noted less frequent events in EZH2, KRAS and TP53. SETD2 was the most frequently silenced gene in HSTL. We experimentally demonstrated that SETD2 acts as a tumor suppressor gene. In addition, we found that mutations in STAT5B and PIK3CD activate critical signaling pathways important to cell survival in HSTL. Our work thus defines the genetic landscape of HSTL and implicates novel gene mutations linked to HSTL pathogenesis and potential treatment targets.

We propose a new prior for ultra-sparse signal detection that we term the "horseshoe+ prior." The horseshoe+ prior is a natural extension of the horseshoe prior that has achieved success in the estimation and detection of sparse signals and has been shown to possess a number of desirable theoretical properties while enjoying computational feasibility in high dimensions. The horseshoe+ prior builds upon these advantages. Our work proves that the horseshoe+ posterior concentrates at a rate faster than that of the horseshoe in the Kullback-Leibler (K-L) sense. We also establish theoretically that the proposed estimator has lower posterior mean squared error in estimating signals compared to the horseshoe and achieves the optimal Bayes risk in testing up to a constant. For global-local scale mixture priors, we develop a new technique for analyzing the marginal sparse prior densities using the class of Meijer-G functions. In simulations, the horseshoe+ estimator demonstrates superior performance in a standard design setting against competing methods, including the horseshoe and Dirichlet-Laplace estimators. We conclude with an illustration on a prostate cancer data set and by pointing out some directions for future research.

Enteropathy-associated T cell lymphoma (EATL) is the most common oncologic complication of celiac disease. Moffitt and colleagues identify novel EATL-defining mutations in SETD2, as well as clinically relevant mutations in the JAK-STAT pathway.